HUTCHMED (China) Limited Sponsored ADR (HCM)
(Delayed Data from NSDQ)
$18.16 USD
-0.83 (-4.37%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $18.16 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
HCM 18.16 -0.83(-4.37%)
Will HCM be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for HCM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HCM
Wall Street Analysts See a 75.05% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?
After Plunging -10.7% in 4 Weeks, Here's Why the Trend Might Reverse for HUTCHMED (HCM)
HCM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 107.24% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?
Wall Street Analysts Think HUTCHMED (HCM) Could Surge 141.13%: Read This Before Placing a Bet
Wall Street Analysts See a 103.84% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?
Other News for HCM
Hutchmed notes CHMP's positive opinion for fruiquintinib approval
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
HUTCHMED’s Fruquintinib Close to EU Approval
Hutchmed announces positive CHMP opinion for fruquintinib
What's Driving HUTCHMED (China) Ltd's Surprising 28% Stock Rally?